NeoGenomics (NEO) director boosts holdings through option and RSU awards
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeoGenomics director Lynn A. Tetrault reported equity award activity and updated holdings. On 2026-06-01, she acquired 23,077 shares of Common Stock through the exercise of previously reported restricted stock units at $0.00 per share, bringing her direct Common Stock holdings to 96,729 shares.
She also received new equity compensation in the form of 15,970 Restricted Stock Units and 11,069 Stock Options with an exercise price of $10.52 per share, both scheduled to vest or become exercisable on 2027-06-01. In addition, she holds 7,000 shares of Common Stock indirectly through the Lynn Tetrault Rollover IRA and maintains several previously granted option positions with exercise prices ranging from $7.28 to $41.76 and expirations through 2035.
Positive
- None.
Negative
- None.
Insider Trade Summary
23,077 shares exercised/converted
Mixed
13 txns
Insider
TETRAULT LYNN A.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 23,077 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 11,069 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 15,970 | $0.00 | -- |
| Exercise | Common Stock | 23,077 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 0 shares (Direct, null);
Stock Option (Right to Buy) — 11,069 shares (Direct, null);
Common Stock — 96,729 shares (Direct, null);
Common Stock — 7,000 shares (Indirect, Lynn Tetrault Rollover IRA)
Footnotes (1)
- Reflects release of restricted stock units that were previously reported on a Form 4. Once vested, the shares of common stock are not subject to expiration.
Key Figures
RSU-derived shares acquired: 23,077 shares
Direct Common Stock holdings: 96,729 shares
Indirect Common Stock holdings: 7,000 shares
+4 more
7 metrics
RSU-derived shares acquired
23,077 shares
Common Stock from RSU exercise on 2026-06-01 at $0.00
Direct Common Stock holdings
96,729 shares
Shares of NeoGenomics Common Stock held directly after 2026-06-01
Indirect Common Stock holdings
7,000 shares
Held via Lynn Tetrault Rollover IRA as of 2026-06-01
New RSU grant
15,970 units
Restricted Stock Units granted 2026-06-01, vesting 2027-06-01
New stock option grant
11,069 options at $10.52
Stock Option (Right to Buy) granted 2026-06-01, expires 2036-06-01
Lowest remaining option strike
$7.28/share
Stock Option (Right to Buy) expiring 2035-06-01, 16,107 underlying shares
Highest remaining option strike
$41.76/share
Stock Option (Right to Buy) expiring 2028-10-11, 972 underlying shares
Key Terms
Restricted Stock Unit, Stock Option (Right to Buy), exercise or conversion of derivative security, grant, award, or other acquisition
4 terms
Restricted Stock Unit financial
"security_title: "Restricted Stock Unit" with 15,970.0000 shares granted"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with various exercise prices"
exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security" for code M"
grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition" for code A"
FAQ
What did NeoGenomics (NEO) director Lynn A. Tetrault report in this Form 4?
Lynn A. Tetrault reported equity award activity, including the vesting of restricted stock units and new grants of restricted stock units and stock options. The filing updates her direct and indirect Common Stock holdings and her remaining option positions.
What new equity awards did Lynn A. Tetrault receive from NeoGenomics (NEO)?
She received 15,970 Restricted Stock Units and 11,069 Stock Options with a $10.52 exercise price. Both awards reference a vesting or exercise date of 2027-06-01, and each unit or option relates to one share of Common Stock.
What derivative positions does Lynn A. Tetrault retain in NeoGenomics stock?
She retains multiple Stock Option (Right to Buy) awards on Common Stock, with exercise prices from $7.28 to $41.76 and expiration dates between 2026-06-06 and 2035-06-01, covering various underlying share amounts.